Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anophthalmia with pulmonary hypoplasia × Head & Neck × Clear all
NCT05005403 2025-10-28

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

AbbVie

Phase 1 Recruiting
512 enrolled
BreastGastrointestinalHead & NeckThoracic

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms